Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CinPhloro Doses First Participant In Phase 2 Enviva Study Of CIN-103 For IBS-D
Details : CIN-103 (phloroglucinol) is a voltage-gated calcium channel blocker. It is being evaluated as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D).
Product Name : CIN-103
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
